- Home
- CRAI vs ETNB Comparison
CRAI vs ETNB Comparison
Compare CRAI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRAI
- ETNB
- Stock Information
- Founded
- CRAI 1965
- ETNB 2018
- Country
- CRAI United States
- ETNB United States
- Employees
- CRAI N/A
- ETNB 93
- Industry
- CRAI Other Consumer Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CRAI Consumer Discretionary
- ETNB Health Care
- Exchange
- CRAI Nasdaq
- ETNB Nasdaq
- Market Cap
- CRAI 1.4B
- ETNB 2.2B
- IPO Year
- CRAI 1998
- ETNB 2019
- Fundamental
- Price
- CRAI $189.98
- ETNB $14.83
- Analyst Decision
- CRAI Buy
- ETNB Buy
- Analyst Count
- CRAI 1
- ETNB 10
- Target Price
- CRAI $235.00
- ETNB $22.31
- AVG Volume (30 Days)
- CRAI 106.7K
- ETNB 9.5M
- Earning Date
- CRAI 10-30-2025
- ETNB 11-06-2025
- Dividend Yield
- CRAI 1.02%
- ETNB N/A
- EPS Growth
- CRAI 44.21
- ETNB N/A
- EPS
- CRAI 8.27
- ETNB N/A
- Revenue
- CRAI $712,913,000.00
- ETNB N/A
- Revenue This Year
- CRAI $9.01
- ETNB N/A
- Revenue Next Year
- CRAI $4.26
- ETNB N/A
- P/E Ratio
- CRAI $23.18
- ETNB N/A
- Revenue Growth
- CRAI 9.28
- ETNB N/A
- 52 Week Low
- CRAI $152.57
- ETNB $4.16
- 52 Week High
- CRAI $214.66
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- CRAI 36.65
- ETNB 79.17
- Support Level
- CRAI $203.37
- ETNB $14.67
- Resistance Level
- CRAI $208.46
- ETNB $14.93
- Average True Range (ATR)
- CRAI 5.71
- ETNB 0.09
- MACD
- CRAI -2.39
- ETNB 0.06
- Stochastic Oscillator
- CRAI 0.97
- ETNB 41.03
About CRAI CRA International Inc.
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).